Glenmark Therapeutics Inc., a US-based company, has announced the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC), a product that is comparable to the active ingredient in MiraLAX Powder for Solution, 17 grams from Bayer HealthCare LLC. According to Nielsen data, the MiraLAX product achieved annual sales of approximately $555.7 million in the latest 52-week period ending February 22, 2025.
The new product marks Glenmark’s entry into the market, which is expected to cater to the growing demand for a new supplier in this category. Marc Kikuchi, President & Business Head, North America at Glenmark, expressed excitement about the launch, stating that it reflects the company’s commitment to meeting market needs and providing high-quality over-the-counter solutions for its customers.
The launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful is expected to give Glenmark a foothold in the market, which has been dominated by MiraLAX. The company’s entry into this category is a significant development, and it will be interesting to see how the market responds to this new competitor. With its commitment to providing high-quality products, Glenmark is likely to make a positive impact in the market. As the company continues to expand its portfolio, it will be worth monitoring to see how it fares in the competitive OTC market.